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 ABSTRACT 
 The dry period is a critical time in the lactation cycle, 
offering the optimum time for cure of existing intra-
mammary infection (IMI), while also encompassing the 
periods of highest susceptibility to new intramammary 
infection. Until recent years, intramammary infection 
in the dry period has been controlled with the use of 
antibiotic dry cow therapy. The aim of this study was 
to investigate 3 different dry cow therapy regimens, in 
low-somatic cell count (SCC; bulk milk SCC < 250,000 
cells/mL) herds in southwest England. A total of 489 
cows was recruited to the study and randomly allo-
cated to receive either the broad-spectrum antibiotic 
cefquinome, a combination treatment comprising the 
narrow-spectrum antibiotic cloxacillin and an internal 
teat sealant, or the narrow-spectrum antibiotic cloxacil-
lin alone. All quarters were sampled for bacteriology 
at drying off and again in the week immediately post-
calving; 2 quarters were also sampled 2 wk before the 
estimated calving date to allow an assessment of infec-
tion dynamics during the dry period. Quarters were 
subsequently monitored for clinical mastitis for the first 
100 d of lactation. Conventional multilevel (random ef-
fects) models were constructed to assess the efficacy of 
products in preventing IMI. Survival analysis was used 
to examine factors that influenced the risk of clinical 
mastitis using conventional Cox proportional hazards 
models. No differences were identified between the 
treatment groups in terms of cure of IMI caused by the 
major pathogens. Quarters in both the combination and 
cefquinome-treated groups were more likely to be free of 
a major pathogen or enterobacterial pathogen postcalv-
ing. With respect to clinical mastitis, the cefquinome-
treated group was less likely to develop clinical mastitis 
than was the cloxacillin treated group. 
 Key words:   dry cow therapy ,  cefquinome ,  intramam-
mary infection ,  broad spectrum 
 INTRODUCTION 
 The dry period has long been acknowledged as a 
crucial period in mastitis control; classically this has 
focused on control of contagious mastitis pathogens 
and culminated in the development and adoption of an-
tibiotic dry cow therapy as a cornerstone of the 5-point 
plan in the 1960s (Neave et al., 1966, 1969; Kingwill et 
al., 1970). Recent research has again highlighted the 
importance of the dry period in mastitis epidemiology 
(Smith et al., 1985; Green et al., 2002a), though follow-
ing the control of the classic contagious mastitis patho-
gens, the environmental pathogens such as Escherichia 
coli and Streptococcus uberis have become significantly 
more important (Bradley and Green, 2004; Bradley et 
al., 2007). This shift in emphasis is as a result in the 
change in the demographic of cows at drying off, away 
from those with an IMI toward those without. This 
change in demographic, coupled with recent research, 
has clearly demarcated the 2 separate roles of dry cow 
therapy, namely the cure of existing and prevention of 
new IMI (Green et al., 2002b; Bradley et al., 2003; 
Bradley and Green, 2004). 
 As outlined above, antibiotic dry cow therapy has 
historically been focused on the control of gram-positive 
pathogens such as Staphylococcus aureus and Strepto-
coccus agalactiae. To this end, many early products 
were narrow spectrum and if gram-negative activity 
was present, it was initially introduced to ameliorate 
against poor infusion technique and accidental inocu-
lation of such pathogens at drying off. Following the 
resurgence of interest in the role of the dry period, one 
such formulation (Ubro Red, Boehringer Ingelheim, 
Bracknell, UK) was assessed for its ability to control 
gram-negative infections. This product was formulated 
containing the aminoglycoside framycetin to enhance 
activity against penicillin-resistant Staph. aureus. Co-
incidentally, framycetin is highly persistent and also 
active against gram-negative organisms and its efficacy 
in gram-negative control in the dry period has been 
demonstrated (Bradley and Green, 2001). A logical 
progression from this initial research was to aim to re-
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duce antibiotic use and instead, attempt to prevent new 
infections by supplementing the cow’s own defenses; to 
this end, the potential role of internal teat sealants was 
investigated and these have also been shown to reduce 
new IMI in cows uninfected at drying off (Berry and 
Hillerton, 2002; Huxley et al., 2002).
This initial research raised a clear dilemma for the 
practitioner. The optimal therapy for cure of persistent 
infections was unlikely to be the optimal therapy for 
prevention of new intramammary infection on a given 
unit. This dilemma led to the use of antibiotics and 
teat sealants in combination and this approach has 
been demonstrated to be efficacious (Godden et al., 
2003; Newton et al., 2008). This approach has clear 
merit; however it also has several drawbacks, namely 
cost (as 2 products are being used, rather than 1), an 
increased risk of damage to the streak canal and in-
oculation of pathogens (2 infusions rather than 1), and 
the resistance of some producers to take this approach, 
especially those supplying cheese manufacturers that 
may have experienced problems with the phenomenon 
described and reported as “black spot defect” in Ched-
dar cheese (Lay et al., 2007).
A recent development among dry cow therapies in 
the EU has been the introduction of the broad-spec-
trum fourth-generation cephalosporin, cefquinome (Ce-
phaguard Dry Cow, Virbac Ltd., Bury St. Edmunds, 
UK). This product potentially offers persistent, broad-
spectrum activity against both gram-positive and 
gram-negative pathogens throughout the dry period, 
affording the opportunity to combine optimal cure 
rates with adequate control of new IMI through to the 
transition period. The aim of the research outlined in 
this paper was to investigate the efficacy of this novel 
product in the control of IMI in the dry period, in low 
bulk milk SCC herds, while concurrently investigating 
the importance of infections acquired in the early dry 
and transition periods and their effect on the incidence 
of clinical mastitis in the first 100 d of the subsequent 
lactation.
MATERIALS AND METHODS
Herd Selection
Eight commercial dairy farms in the southwest of 
England were enrolled in the study. Herds were eligible 
for inclusion in the study if they had appropriate cow 
identification and recording of health data, were en-
rolled in an individual cow milk recording scheme to 
allow collation of historic SCC data, and had a bulk 
milk SCC <300,000 cells/mL. Herds were then selected 
on the basis of existing records and an anticipated ac-
ceptable level of compliance. Each site was visited by 
a veterinarian, to provide suitable training to ensure 
protocol compliance.
Cow Selection
Prior to enrollment, cows were inspected by a member 
of the study team and were eligible if they were in good 
health and had 4 functional quarters free of significant 
teat lesions (e.g., cuts and deformities). Cows that had 
received systemic or intramammary antibiotics or anti-
inflammatories in the 30 d before the last milking were 
not enrolled in the study.
Study Protocol
Enrollment. Farms were visited weekly, and cows 
were enrolled in the study on the day of drying off. At 
enrollment, key cow details including parity, estimated 
milk yield, individual cow SCC history, treatment his-
tory and estimated calving date, were collated from 
farm records. Prior to the final milking in the lactation 
and before treatment administration, each animal was 
identified and physically examined by a member of the 
study team for suitability on the basis of the exclusion 
criteria. Duplicate milk samples were then collected 
for bacteriological examination and a single sample for 
SCC evaluation was made from each quarter of each 
eligible animal using a method described previously 
(Bradley and Green, 2000).
Treatment Allocation and Administration. On 
the day of dry off, cows were randomly allocated to 
receive one of the 3 treatments. The 3 treatment groups 
comprised either broad-spectrum antibiotic treatment 
with the fourth-generation cephalosporin cefquinome 
(treatment group CDC; 150 mg of cefquinome; Cepha-
guard Dry Cow, Virbac Ltd.), combination treatment 
comprising narrow-spectrum cloxacillin and an internal 
teat sealant (treatment group COMBO; 600 mg of 
cloxacillin; Orbenin Extra Dry Cow, Pfizer Animal 
Health, Sandwich, UK) and (65% of bismuth subnitrate 
in a mineral oil base; OrbeSeal, Pfizer Animal Health), 
or narrow-spectrum antibiotic treatment comprising 
cloxacillin alone (treatment group OEDC; 600 mg 
of cloxacillin; Orbenin Extra Dry Cow, Pfizer Animal 
Health). Within herds, cows were randomly allocated 
to a treatment group using a randomization table and 
a block design to ensure a “tight” temporal allocation 
of treatments on individual units— this was necessary 
to ensure a comparable environmental challenge in each 
treatment group. Dry cow therapy was administered 
by a member of the study personnel following aseptic 
precautions. Following treatment administration, quar-
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ters were dipped with a postmilking disinfectant and 
confined to a loafing yard for at least 30 min before 
moving to accommodation.
Dry Period Management and Sampling. Fol-
lowing treatment, and until calving, study animals were 
subjected to the usual dry cow husbandry practices for 
the farm and regularly observed by the owner/herd-
sperson or other suitably qualified person. Any disease 
or concurrent treatments were recorded. All cases of 
clinical mastitis were recorded and sampled.
At approximately 2 wk before the estimated date of 
calving, duplicate samples for bacteriology were col-
lected from 2 ipsilateral quarters of each of the cows 
according to line number (i.e., odd numbered cows 
sampled on the left and even numbered cows sampled 
on the right)—this approach was necessary to address 
any potential proclivity, due to housing design, of cows 
to lie on 1 side and any temporal variation in chal-
lenge, given that environmental pathogens are the most 
likely cause of infection in the dry period in the modern 
dairy herd. Samples were collected using a strict asep-
tic technique after which quarters were dipped with a 
postmilking disinfectant and confined to a loafing yard 
for at least 30 min before returning to their accom-
modation.
At Calving. Cows were managed following normal 
husbandry practices on each of the participating farms. 
Animals were inspected by the herdsperson/owner im-
mediately postcalving, with particular attention paid 
to udder health. Any physical abnormalities detected 
or conditions treated were recorded.
Postcalving. Duplicate quarter milk samples were 
collected for bacteriological examination at the first 
weekly visit after each cow had calved. At the same 
time, a milk sample was taken from each quarter for 
enumeration of the quarter SCC. Samples collected 
more than 10 d after calving were excluded from the 
analysis of efficacy as measured by the cure or acquisi-
tion of IMI during the dry period.
Clinical Mastitis Monitoring. Farm personnel, 
trained in the detection and aseptic sampling of clinical 
mastitis, monitored cows for the presence of clinical 
mastitis throughout the study period (from dry off 
until 100 d postcalving) and collected a pretreatment 
quarter milk sample, using aseptic technique, when 
cases occurred. These samples were frozen on the farm 
and stored until the next routine visit.
Laboratory Procedures
All milk samples collected were maintained at or be-
low 8°C during transport to the laboratory for analysis. 
Microbiological investigation and somatic cell counts 
were carried out using the standard milk sample exami-
nation techniques, which exceeded the standard recom-
mended by the International Dairy Federation (Bulletin 
No 132, 1981), International Standard 13366–1:1997 
(E) and 13366–2:1997 (G). A more detailed description 
of these techniques is outlined below.
Bacteriology. Ten microliters of secretion was in-
oculated onto sheep blood agar and Edward’s agar; 100 
μL of secretion was inoculated onto MacConkey agar 
to enhance the detection of Enterobacteriaceae. Plates 
were incubated at 37°C and read at 24, 48, and 72 h. 
Organisms were identified and quantified using standard 
laboratory techniques (Quinn et al., 1994; NMC, 1999). 
Escherichia coli were identified by colony morphology, 
oxidase and indole tests. Other Enterobacteriaceae 
were identified using a microtube identification system 
(RapiD 20 E, bioMérieux, Basingstoke, UK).
Somatic Cell Counting. Somatic cell count was 
determined using the Fossomatic method (Delta Com-
biScope—Model FTIR 400, Drachten, the Netherlands), 
according to the FIL .IDF 148 A: 95 norm.
Assessment of Efficacy
Isolation of an organism was taken to be indicative 
of IMI. A sample was considered contaminated if more 
than 3 pathogens were cultured from a sample. If this 
occurred, then the duplicate sample was submitted for 
bacteriological analysis (Bradley and Green, 2000). 
Several outcomes were assessed as outlined below.
Cure of Existing IMI. The overall and species-
specific percentage cured was estimated and compared 
between groups. A cure was defined as the absence of 
a pathogen in the postcalving sample that had been 
present at drying off.
Acquisition of New IMI. The overall and species-
specific percentages of new infections were estimated 
and compared between groups. A new infection was 
defined as the presence of a pathogen in the postcalving 
sample that had not been present at drying off. There-
fore, a quarter infected with 1 pathogen at drying off 
was eligible to acquire a new infection with a different 
pathogen.
Successful Dry Period Outcome. Successful dry 
period outcomes were estimated and compared between 
groups using methods described previously (Newton 
et al., 2008). A successful outcome was defined in 2 
ways; first, as the absence of a major pathogen from the 
postcalving sample and second, as the absence of any 
mastitis pathogen (major or minor) from the postcalv-
ing sample.
Incidence of Clinical Mastitis in the First 100 
Days of the Subsequent Lactation. The overall 
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and species-specific incidences of clinical mastitis were 
assessed in the first 100 d of lactation and compared 
between treatment groups.
Analysis of Events Occurring Within the Dry Period
In addition to the analyses described above, a more 
in-depth exploration of the data was undertaken to 
describe the apparent dynamics of intramammary in-
fection during the dry period; this analysis was under-
taken for descriptive purposes only. More specifically, 
in the subset of quarters sampled during the dry period 
(between 7 and 21 d precalving) the change in infection 
status was assessed between drying off and the transi-
tion sample and also between the transition sample and 
calving, allowing a description of the timing of appar-
ent cures and new IMI within the dry period accord-
ing to the criteria outlined for the entire dry period as 
outlined above.
Data Collation and Statistical Analyses
Data were collated and initially analyzed using Ex-
cel and Access 2003 (Microsoft Corp., Redmond, WA) 
and Minitab 15.1 (Minitab Inc., State College, PA). 
Descriptive and graphical analyses were carried out to 
explore the data. Mann-Whitney and Wilcoxon tests 
were used to compare the treatment groups where ap-
propriate. Univariable analysis of treatment efficacy 
was performed using the Chi-Square test to investigate 
differences in proportions between groups; a layered 
Bonferroni correction was used to allow for multiple 
comparisons where appropriate (Darlington, 1990).
When assessing the efficacy of products in control of 
intramammary infection, conventional multilevel (ran-
dom effects) models (Goldstein, 1995) were specified 
so that correlations within the data (quarters within 
cows) were accounted for appropriately. Model specifi-
cations were
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ij ij
ij ij j
~Bernoulli probability
Logit
=( )
( ) = + + +
π
π α β β1 2 k j
j u
u
u N
+
( )~ , ,0 2σ
 
where the subscripts i and j denote the ith quarter and 
the jth cow, respectively, α the regression intercept, Xij 
the vector of covariates at quarter level, β1 the coeffi-
cients for covariates Xij, Xj the vector of cow level cova-
riates, β2 the coefficients for covariates Xj, herdk is a 
fixed effect for the kth herd, and uj is a random effect 
to reflect residual variation between cows that is nor-
mally distributed with mean = 0 and variance = σu2.
Covariate assessment and selection was carried out 
using MLwiN with penalized quasi-likelihood for pa-
rameter estimation (Rasbash et al., 2005). Covariates 
remained in the model when the 95% confidence inter-
vals for the odds ratios did not include 1.00. Investiga-
tion of model fit was made from plots of cumulated fit-
ted probabilities and residuals, as described previously 
(Green et al., 2004).
Survival analysis was used to examine factors that 
influenced the risk of clinical mastitis at the cow level 
in the first 100 d of lactation. A conventional Cox pro-
portional hazards model was specified (Collett, 1994). 
The standard model can be summarized as
 λ λ βi X= × ′ ′( )0 exp ,  
where λi = hazard function (instantaneous risk of clini-
cal mastitis in cow i at time t, where t is the time from 
calving to 100 d postcalving), λ0 = baseline hazard, and 
β′X′ = linear predictor containing a series of explana-
tory covariates X′, with regression coefficients β′.
Parameter estimates were made using Egret (Vs 
2.0.3, Cytel Software Corp., Cambridge, MA). The sig-
nificance probability (α) was set at 0.05 and parameter 
significance assessed using the likelihood ratio test. In 
order to check that the assumption of proportionality 
of hazards was correct (Collett, 1994), a visual assess-
ment was performed of the log-transformed cumulative 
hazard for the explanatory variables.
RESULTS
A total of 489, predominantly Holstein-Friesian, cows 
were enrolled between February and June from the 8 
farms in the study; 161, 164, and 164 to the CDC, 
COMBO, and OEDC groups, respectively. Details of 
the number of cows recruited from each farm and sa-
lient farm management details are outlined in Table 
1. Data from 449 and 460 cows were incorporated into 
the analyses pertaining to dry period IMI and clini-
cal mastitis, respectively. Twenty-nine animals were 
not available for inclusion in the analyses. Reasons for 
this were: animals were either not pregnant or calved 
beyond the end of the study (n = 18) and animals not 
sampled within 10 d postcalving (n = 11). Animals 
that were concurrently treated after the postcalving 
sample had been collected were included in the clini-
cal mastitis survival analysis, but were censored at the 
time of treatment.
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Univariable Analysis
The key indices and parameters relating to animals 
included in the final analysis of efficacy are summarized 
in Table 2. No significant differences were detected be-
tween treatment groups in any of the key indices such 
as parity, yield before drying off, dry period length, or 
SCC at the end of the previous lactation.
Prevalence of Infection. The prevalence of the 
key mastitis pathogens at drying off and postcalving in 
each of the treatment categories are outlined in Table 3. 
No significant differences between the treatment groups 
in the prevalence of infection at dry off were identi-
fied. However, significant differences were found in the 
prevalence of pathogens present postcalving. Quarters 
in the CDC and COMBO groups were less likely to be 
infected with Strep. uberis than those in the OEDC 
group (11/584, 13/616 vs. 28/596, respectively; P < 
0.05), an enterobacterial organism (20/584, 17/616 vs. 
37/596, respectively; P < 0.05), or with a major patho-
gen overall (64/584, 52/616 vs. 96/596, respectively; P 
< 0.05). Quarters in the COMBO group, although not 
significantly different from those in the CDC group, 
were less likely to be infected with E. coli than were 
quarters in the OEDC group (20/584, 14/616 vs. 
34/596, respectively; P < 0.05). When the likelihood of 
being free of any pathogen postcalving was considered, 
then quarters in the COMBO group were more likely 
(427/616 vs. 357/596; P < 0.05) to be pathogen-free 
posttreatment than quarters in the OEDC group; re-
sults from CDC-treated quarters were not significantly 
different from either of the other treatment groups.
Apparent Percentage of Dry Period Cures. The 
pathogen-specific apparent number of cures for the key 
mastitis pathogens are outlined in Table 4. No signifi-
cant differences in the apparent percentage of cures were 
identified for any of the major pathogens; however, the 
apparent percentage of cures of CNS were significantly 
higher in the COMBO group (169/202 COMBO vs. 
138/189 CDC, 139/194 OEDC; P < 0.05) compared 
with those in either of the other groups.
Apparent Dry Period Percentage of New IMI. 
The pathogen-specific apparent number of new IMI for 
the key mastitis pathogens are outlined in Table 5. No 
significant differences in the apparent percentage of new 
infections were identified for any of the gram-positive 
major pathogens. However, the apparent percentages of 
new infections for E. coli (20/562 CDC, 14/602 COMBO 
vs. 31/575 OEDC; P < 0.05) and all enterobacteriaceae 
combined (20/559 CDC, 17/598 COMBO vs. 35/575 
OEDC; P < 0.05) were lower in the COMBO group 
compared with those of the OEDC group, whereas they 
were not significantly different from those of the CDC 
group.
Dry Period Outcomes. Dry period outcomes for 
each of the treatment groups are summarized in Table 
6. Whereas no significant difference existed in the pro-
portion of quarters acquiring an infection during the 
dry period, a difference existed in the proportion of 
quarters experiencing an apparent dry period cure and 
in the proportion of quarters pathogen-free posttreat-
ment. Quarters in the COMBO group were more likely 
to experience a dry period cure (305/613 vs. 255/588; P 
< 0.05) and be pathogen-free postcalving (426/613 vs. 
356/588; P < 0.05) than were quarters in the OEDC-
treated quarters. Results for the quarters in the CDC 
group were not significantly different from those in 
either of the other treatment groups.
Clinical Mastitis. A total of 158 quarter cases of 
clinical mastitis occurred in the 460 cows eligible for 
inclusion in the analysis: 46, 48, and 64 in the quarters 
in the CDC, COMBO, and OEDC groups, respectively. 
Clinical cases with enterobacterial involvement were the 
most common, accounting for 58% of cases from which 
a major pathogen was identified; contagious mastitis 
pathogens were rarely identified. For the purposes of 
assessing efficacy, only the first case to occur in a quar-
ter during the study period was considered to mitigate 
the risk of confounding effects of treating a case in 1 
quarter on outcomes in another in the same cow. Table 
7 summarizes the findings from the first case of clini-
cal mastitis to occur in each cow, at which point they 
would have been censored from the study. Univariable 
analysis of the first case of clinical mastitis to occur in 
each cow revealed that cows in the COMBO group were 
significantly less likely to develop clinical enterobacte-
rial mastitis than were cows in the OEDC group (4/154 
vs. 15/155, respectively; P < 0.05). Results from cows 
in the CDC group were not significantly different from 
those in either of the other treatment groups.
Description of Events Occurring  
During the Dry Period
Transition samples were collected from 586 quarters 
across all 3 treatment groups; samples were not col-
lected from approximately 300 eligible quarters due 
to the cows being unavailable for sampling (at distant 
pasture) or due to cows calving earlier than expected. 
A summary of the findings are outlined in Table 8. 
Unfortunately, insufficient data were available to allow 
a meaningful comparison between treatment groups 
and care needs to be taken in interpreting the findings. 
However, investigation of the available data suggests 
that the majority of apparent cures occurred in the 
early dry period and that, in this study, few infections 
persisted from drying off until the subsequent lactation. 
The apparent new infection rate before transition was 
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Table 1. Key characteristics of the 8 study farms 
Item
Farm identification
B C F G H R S T
Approximate herd size (cows in milk) 310 480 200 280 220 420 150 610
Proportion of recruited animals at the end of lactation 1 0.11 0.47 0.19 0.36 0.39 0.35 0.43 0.43
Number of animals recruited 18 96 53 61 41 63 54 103
Geometric mean bulk milk SCC (×1,000 cells/mL) in the 5 mo before the study 213 194 172 162 218 195 163 163
Dry cow winter housing1 Y C, Y C, Y C, Y Y C, Y C Y
Predominant dry cow summer housing1 P P C, Y P P P P Y
Predominant dry cow bedding Straw Sand Sand Straw Straw Straw Straw Straw
1C = freestalls; Y = covered straw yards; P = pasture.
Table 2. Summary of data from cows and quarters included in the analysis of product efficacy as measured by cure and acquisition of IMI during the dry period1 
Item
CDC (n = 146, q = 584) COMBO (n = 154, q = 616) OEDC (n = 149, q = 596)
Mean Med. Min. Max. Mean Med. Min. Max. Mean Med. Min. Max.
Parity 2.59 2 1 10 2.45 2 1 8 2.51 2 1 11
Yield at dry off (L) 15.2 15 1 40 15.3 15 2 43 15.7 15 2 40
Dry period length (d) 62.3 59 18 171 64.3 59 27 225 62.7 57 26 169
ICSCC2 1 mo before dry off (×1,000 cells/mL) 311 168 10 2,558 237 147 14 1,656 261 157 13 1,663
ICSCC 2 mo before dry off (×1,000 cells/mL) 205 105 10 3,742 183 110 7 2,875 216 106 8 2,100
ICSCC 3 mo before dry off (×1,000 cells/mL) 155 99 13 1,489 142 104 10 929 190 105 5 1,946
1CDC = group treated with cefquinome; COMBO = group treated with cloxacillin in combination with internal teat sealant; OEDC = group treated with cloxacillin alone; q = 
number of quarters; Med. = median; Min. = minimum; Max. = maximum.
2Individual cow SCC. 
not dissimilar to that seen in the transition period, 
though importantly, few of these apparent infections 
persisted until the postcalving sample, with most 
appearing to resolve spontaneously. On the basis of 
the data collected in this study, no gram-negative 
infections appeared to originate from the early dry 
period, whereas between 10 and 50% of gram-posi-
tive infections originated from before the transition 
period.
Multivariable Analysis
Dry Period Outcomes. Two different outcomes 
were modeled: the likelihood of a quarter being free 
of a major mastitis pathogen postcalving (Table 9) 
and of being infected with an enterobacterial patho-
gen postcalving (Table10). The potential confounding 
influence of the presence of infection at drying off was 
tested in all models, as was the influence of yield at 
drying off, dry period length, parity, farm, SCC before 
drying off, and the influence of collection of a transition 
sample. Compared with quarters in the OEDC group, 
quarters in the COMBO group (odds ratio, OR, 2.01; 
95% CI, 1.32 to 3.07) and CDC group (OR 1.61; 95% 
CI 1.07 to 2.43) had increased the odds of being free of 
a major mastitis pathogen postcalving; no difference 
between the COMBO and CDC groups existed. Parity 
1 cows entering their second parity had increased odds 
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Table 3. The prevalence of mastitis pathogens (n; % in parentheses) at drying off and postcalving, restricted to quarters and cows eligible for 
assessment of product efficacy1 
Item
CDC (q = 584) COMBO (q = 616) OEDC (q = 596)
Dry off Postcalving Dry off Postcalving Dry off Postcalving
Streptococcus uberis 16 (2.74) 11 (1.88)a 10 (1.68) 13 (2.18)a 16 (2.60) 28 (4.55)b
Streptococcus dysgalactiae 2 (0.34) 1 (0.17) 3 (0.50) 0 (0) 7 (1.14) 3 (0.49)
Coagulase-positive staphylococci 5 (0.86) 2 (0.34) 4 (0.67) 2 (0.34) 3 (0.49) 4 (0.65)
Escherichia coli 15 (2.57) 20 (3.42)ab 11 (1.85) 14 (2.35)a 13 (2.11) 34 (5.52)b
Other enterobacteriaceae 3 (0.51) 0 (0) 4 (0.67) 3 (0.50) 0 (0) 3 (0.49)
Aerococcus spp. 22 (3.77) 10 (1.71) 27 (4.53) 6 (1.01) 27 (4.38) 15 (2.44)
Arcanobacterium pyogenes 0 (0) 1 (0.17) 0 (0) 1 (0.17) 0 (0) 5 (0.81)
Other major pathogens 10 (1.71) 20 (3.42) 10 (1.68) 16 (2.68) 18 (2.92) 13 (2.11)
All enterobacteriaceae 18 (3.08) 20 (3.42)a 15 (2.52) 17 (2.85)a 13 (2.11) 37 (6.01)b
All major pathogens2 70 (11.99) 64 (10.96)a 66 (10.71) 52 (8.44)a 82 (13.76) 96 (16.11)b
CNS 189 (32.36) 133 (22.77) 202 (33.89) 113 (18.96) 194 (31.49) 141 (22.89)
Corynebacterium spp. 308 (52.74) 72 (12.33) 340 (57.05) 56 (9.40) 340 (55.19) 77 (12.50)
All minor pathogens2 329 (56.34) 150 (25.68) 376 (61.04) 135 (21.92) 348 (58.39) 143 (23.99)
No growth 178 (30.48) 370 (63.36)ab 172 (27.92) 427 (69.32)a 158 (26.51) 357 (59.90)b
Contaminated 7 (1.20) 0 (0) 2 (0.32) 1 (0.16) 8 (1.34) 0 (0)
a,bValues in columns between treatment groups and within sampling time points with different superscripts differ (P < 0.05).
1CDC = group treated with cefquinome; COMBO = group treated with cloxacillin in combination with internal teat sealant; OEDC = group 
treated with cloxacillin alone; q = number of quarters.
2Totals may not equal sum of the individual pathogens due to mixed infections.
Table 4. The apparent dry period number and percentage of cures of the key mastitis pathogens1 
Item
CDC COMBO OEDC
n2 % n % n %
Streptococcus uberis 16 100 10 80 16 75
Streptococcus dysgalactiae 2 100 3 100 7 100
Coagulase-positive staphylococci 5 100 4 100 3 66.67
Escherichia coli 15 100 11 100 13 92.31
Other enterobacteriaceae 3 100 4 100 0 NA3
Aerococcus spp. 22 100 27 100 27 100
Arcanobacterium pyogenes 0 NA 0 NA 0 NA
Other major pathogens 10 100 10 100 18 100
CNS 189 73.02a 202 83.7b 194 71.65a
Corynebacterium spp. 308 87.99 340 91.8 340 85.59
a,bValues in columns with different superscripts differ (P < 0.05).
1CDC = group treated with cefquinome; COMBO = group treated with cloxacillin in combination with internal teat sealant; OEDC = group 
treated with cloxacillin alone.
2n = number of quarters infected at drying off.
3NA = not applicable.
of being free of a major mastitis pathogen compared 
with the odds for parity 3 and above cows. Other fac-
tors were found not to be influential.
When compared with quarters in the OEDC group, 
quarters in the COMBO (OR 0.39; 95% CI 0.24 to 
0.61) and CDC (OR 0.53; 95% CI 0.34 to 0.82) groups 
had reduced odds of being infected with an enterobac-
terial mastitis pathogen postcalving; no difference was 
found between the COMBO and CDC groups. Parity 1 
and 2 cows entering their second and third parities had 
reduced odds of being infected with an enterobacterial 
mastitis pathogen than did parity 3 and above cows. 
Irrespective of treatment group, significant variation 
existed between farms. Collection of a transition sample 
within 1 wk of calving significantly increased the risk of 
a cow being infected with an enterobacterial pathogen 
postcalving, though again this was irrespective of treat-
ment group; interestingly, further analysis suggested 
that combination treated quarters were least likely to 
be affected by transition sampling. Other factors, such 
as SCC before drying off, yield at drying off, dry period 
length, and previous clinical mastitis history were not 
found to be influential.
Clinical Mastitis. Multivariable analysis was con-
ducted at the cow level, using only the 2 quarters that 
had not been sampled during the transition period, 
thereby controlling for this potentially confounding fac-
tor. A conventional Cox proportional hazards model 
was specified, a summary of which is outlined in Table 
11. A survival plot is illustrated in Figure 1. Cows in 
the CDC group were the least likely to develop clinical 
mastitis. Results from cows in both the CDC (hazard 
ratio 0.49; 95% CI 0.25 to 0.93) and COMBO (HR 0.57; 
95% CI 0.31 to 1.03) groups were similar and at lower 
risk of developing clinical mastitis than those from cows 
in the OEDC group. Parity, farm, and the presence of a 
major pathogen present at drying off had no significant 
effect on the likelihood of developing clinical mastitis in 
the early part of the next lactation. Other factors, such 
as SCC before drying off, yield at drying off, dry period 
length, and previous clinical mastitis history were also 
found not to be influential.
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Table 5. The apparent dry period number and percentage of new IMI for the key mastitis pathogens1 
Item
CDC COMBO OEDC
n2 New IMI3 % n New IMI % n New IMI %
Streptococcus uberis 561 12 2.14 603 11 1.82 572 24 4.20
Streptococcus dysgalactiae 575 1 0.17 610 0 0.00 581 3 0.52
Coagulase-positive staphylococci 572 2 0.35 609 2 0.33 585 2 0.34
Escherichia coli 562 20 3.56ab 602 14 2.33a 575 31 5.39b
Other enterobacteriaceae 574 0 0.00 609 3 0.49 588 4 0.68
Aerococcus spp. 555 10 1.80 586 6 1.02 561 15 2.67
Arcanobacterium pyogenes 580 1 0.17 613 1 0.16 588 5 0.85
Other major pathogens 567 20 3.53 603 16 2.65 570 13 2.28
All enterobacteriaceae 559 20 3.58ab 598 17 2.84a 575 35 6.09b
CNS 388 81 20.88 411 79 19.22 394 84 21.32
Corynebacterium spp. 269 34 12.64 273 28 10.26 248 27 10.89
a,bValues in columns with different superscripts differ (P < 0.05).
1CDC = group treated with cefquinome; COMBO = group treated with cloxacillin in combination with internal teat sealant; OEDC = group 
treated with cloxacillin alone.
2n = number of quarters uninfected with the pathogen at drying off.
3New IMI = number of new IMI acquired during the dry period.
Table 6. A summary of the quarter level dry period outcomes for each of the treatment groups1 
Item CDC COMBO OEDC
Quarters treated (n) 577 613 588
Quarters infected at drying off (n) 399 441 430
Quarters experiencing an apparent dry period cure (n) 248ab 305a 255b
Quarters uninfected at drying off (n) 178 172 158
Quarters becoming infected during the dry period (n) 56 51 57
Quarters uninfected postcalving (n) 370ab 426a 356b
a,bValues in columns with different superscripts differ (P < 0.05).
1CDC = group treated with cefquinome; COMBO = group treated with cloxacillin in combination with inter-
nal teat sealant; OEDC = group treated with cloxacillin alone. Values may differ from Tables 3, 4, and 5 due 
to exclusion of data from quarters where a sample was contaminated either at drying off or postcalving.
DISCUSSION
The data and results outlined in this study dem-
onstrate the efficacy of the fourth-generation cepha-
losporin, cefquinome when incorporated in a dry cow 
formulation (Cephaguard Dry Cow, Virbac Ltd) in 
the treatment and prevention of IMI in nonlactating 
dairy cows. In addition, cefquinome has been demon-
strated to significantly reduce the likelihood of a cow 
developing clinical mastitis in the first 100 d of the 
subsequent lactation compared with that from the use 
of a narrow-spectrum cloxacillin-containing formula-
tion. Much of the apparent enhanced benefit compared 
with cloxacillin appeared to be as a result of control of 
infection with enterobacterial species and a subsequent 
decrease in enterobacterial clinical mastitis in the early 
part of the subsequent lactation. This study has inves-
tigated the efficacy of the very broad-spectrum fourth-
generation cephalosporin, cefquinome. It would be of 
great value to the practitioner to know if earlier gen-
eration cephalosporins could offer similar benefits over 
narrow-spectrum dry cow products. One would expect 
increasing efficacy against gram-negative pathogens as 
one moved through the cephalosporin generations and 
the spectrum of activity increased; however, given the 
importance of persistence of activity to the back end of 
the dry period, this would inevitably be affected by du-
ration of activity, which is also likely to be formulation 
dependant—this is an area in need of further research 
to enable the practitioner to make more evidence-based 
decisions on product selection.
The use of intramammary dry cow therapy with per-
sistent gram-negative activity has previously been dem-
onstrated to control enterobacterial clinical mastitis in 
the subsequent lactation (Bradley and Green, 2001). 
This is the first study to have compared the use of 
an internal teat sealant, either alone or in combination 
with antibiotic, with a broad-spectrum dry cow therapy 
with persistent activity. Interestingly, the cefquinome 
formulation appeared to have similar efficacy to that of 
narrow-spectrum dry cow therapy used in combination 
with an internal teat sealant. This finding was surpris-
ing, as it necessitates the persistence of gram-negative 
activity until the transition period, a fact reinforced by 
the finding that those gram-negative infections present 
at calving appear to have exclusively originated from 
the latter part of the dry period.
The dynamics of the cure and new IMI processes 
in this study are complex and not easy to elucidate. 
Whereas at the species level, no significant difference 
was found in percentage of cures, with the exception of 
the CNS, a significant difference was found in the ef-
ficacy of the products when measured by the likelihood 
of an infected quarter being free of a major pathogen. 
A strong rationale exists for taking this approach to 
assessment of dry cow therapy, because the clinical out-
Journal of Dairy Science Vol. 94 No. 2, 2011
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Table 7. Summary of first quarter cases of clinical mastitis occurring in each cow, in cows recruited to the 
study and eligible for inclusion in the analysis of efficacy as measured by the occurrence of clinical mastitis1 
Diagnosis CDC COMBO OEDC
Number of quarters (cows) at risk 604 (151) 616 (154) 620 (155)
Escherichia coli 6 4 12
Streptococcus uberis 1 3 2
Streptococcus dysgalactiae 1 3  
Staphylococcus aureus 1  1
Klebsiella spp.   1
Yeast spp. 1   
Bacillus spp.  1 1
Aerococcus spp. 1  2
Arcanobacterium pyogenes 1 1 2
E. coli and Strep. uberis 1  1
Klebsiella spp. and Aerococcus spp. 1   
Strep. uberis and Staph. aureus 1   
E. coli and Strep. dysgalactiae   1
Total cases with mixed etiology 3 0 2
Total cases with enterobacterial involvement 8ab 4a 15b
Total major pathogens 15 12 23
CNS 2   
Corynebacterium spp.  1  
Total minor pathogens 2 1 0
No growth 1 6  
No sample 7 12 14
Total cases 25 31 37
a,bValues in columns with different superscripts differ (P < 0.05).
1CDC = group treated with cefquinome; COMBO = group treated with cloxacillin in combination with inter-
nal teat sealant; OEDC = group treated with cloxacillin alone.
come of most significance to the farmer is the propor-
tion of quarters pathogen-free at calving. Arguably, this 
approach to assessment of efficacy of dry cow therapy 
is most relevant in herds with relatively lower bulk 
milk SCC, in which both the prevalence of infection 
at drying off is lower and the infectious pressure with 
contagious pathogens is reduced.
Whereas combination treatment and treatment with 
cefquinome exhibited similar efficacy against major 
mastitis pathogens, arguably, minor pathogens were 
better controlled using the combination treatment. This 
is of interest, as one might speculate that persistence of 
minor pathogens and the effect this may have on gland 
susceptibility, either as a result of moderate elevation in 
SCC or competitive exclusion, may, in part, explain the 
lower incidence of clinical mastitis in the cefquinome-
treated group compared with that of the combination-
treated group. Unfortunately, sufficient power in this 
study was not available to investigate this effect, but it 
could be a fruitful area of further research.
The relationship between intramammary infection 
in the nonlactating period and clinical mastitis in the 
early part of the subsequent lactation has been an area 
of recent research (Bradley and Green, 2000; Green et 
al., 2002a). This study, in common with several oth-
ers, has reinforced the importance of the dry period 
in clinical mastitis epidemiology and should aid the 
practitioner in making evidence-based decisions about 
dry cow therapy selection.
This study, along with several other recent stud-
ies undertaken by the authors (Newton et al., 2008; 
Bradley et al., 2010), has demonstrated how effective 
antibiotic dry cow therapy is in removing persistent 
infections present at drying off in the modern low 
SCC dairy herd. These findings should reiterate to the 
practitioner the importance of prevention of new intra-
mammary infection during the dry period, because less 
than 1.9% (4/212) of major pathogen infections pres-
ent postcalving had apparently persisted from drying 
off. This observation should call into question the cost 
benefit of the use of additional parenteral antibiotic 
therapies as a supplement to dry cow therapy in such 
herds, and should instead focus the practitioner and 
herdsperson alike on minimizing challenge rather than 
focusing on cure.
CONCLUSIONS
This study has demonstrated the utility of a persis-
tent broad-spectrum antibiotic dry cow therapy, con-
taining cefquinome, in the treatment and prevention of 
intramammary infection during the nonlactating period 
of dairy cattle. It has also reiterated the importance of 
prevention of new intramammary infection in the dry 
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Table 9. Summary of the multilevel model, free of a major pathogen postcalving 
Item Coefficient SE
Odds  
ratio
95% CI
Lower Upper
Treatment (ref1 OEDC)2
 COMBO 0.70 0.21 2.01 1.32 3.07
 CDC 0.48 0.21 1.61 1.07 2.43
Pathogen identified      
 Cow major @ DO3 −0.21 0.18 0.82 0.56 1.18
Parity (ref parity 3 and above)      
 Parity 1 0.46 0.21 1.58 1.04 2.41
 Parity 2 0.42 0.23 1.52 0.96 2.39
Farm (ref Farm_B)      
 Farm_C −0.38 0.55 0.68 0.23 2.03
 Farm_F −0.60 0.55 0.55 0.18 1.66
 Farm_G −0.50 0.55 0.61 0.20 1.82
 Farm_H −0.35 0.60 0.71 0.21 2.32
 Farm_R 0.11 0.58 1.12 0.35 3.60
 Farm_S −0.62 0.56 0.54 0.17 1.65
 Farm_T −0.82 0.54 0.44 0.15 1.31
Sample collection time (ref TR TIME CAT_1)4      
 TR TIME CAT_2 0.13 0.33 1.14 0.59 2.19
 TR TIME CAT_3 0.31 0.34 1.36 0.69 2.68
 TR TIME CAT_4 −0.07 0.36 0.93 0.45 1.92
 TR TIME CAT_999 0.24 0.44 1.27 0.52 3.06
1Referent sample.
2OEDC = group treated with cloxacillin alone; COMBO = group treated with cloxacillin in combination with internal teat sealant; CDC = 
group treated with cefquinome. 
3Cow major @ DO: a major pathogen identified in any quarter at drying off.
4TR TIME CAT_1: sample collected 1–7 d precalving; TR TIME CAT_2: sample collected 8–14 d precalving; TR TIME CAT_3: sample col-
lected 15–21 d precalving; TR TIME CAT_4: sample collected >21 d precalving; TR TIME CAT_999: no transition period milk sample col-
lected.
Table 10. Summary of the multilevel model, infected with an enterobacterial pathogen postcalving 
Item Coefficient SE
Odds  
ratio
95% CI
Lower Upper
Treatment (ref1 OEDC)2
 COMBO −0.95 0.23 0.39 0.61 0.24
 CDC −0.64 0.22 0.53 0.82 0.34
Parity (ref parity 3 and above)      
 Parity_1 −0.23 0.22 0.79 1.23 0.51
 Parity_2 −0.02 0.24 0.98 1.58 0.61
Farm (ref Farms_B and T)      
 Farm_C −0.40 0.59 0.67 2.18 0.21
 Farm_F 0.33 0.59 1.39 4.53 0.43
 Farm_G −1.77 0.59 0.17 0.55 0.05
 Farm_H −0.64 0.65 0.53 1.93 0.16
 Farm_R −0.44 0.63 0.64 2.27 0.18
 Farm_S 0.53 0.60 1.70 5.64 0.51
Sample collection time (ref TR TIME CAT_1)3      
 TR TIME CAT_2 −0.47 0.34 0.63 1.23 0.32
 TR TIME CAT_3 −0.94 0.35 0.39 0.79 0.19
 TR TIME CAT_4 −0.52 0.38 0.59 1.27 0.28
 TR TIME CAT_999 −1.74 0.49 0.18 0.47 0.07
1Referent sample.
2OEDC = group treated with cloxacillin alone; COMBO = group treated with cloxacillin in combination with internal teat sealant; CDC = 
group treated with cefquinome. 
3TR TIME CAT_1: sample collected 1–7 d precalving; TR TIME CAT_2: sample collected 8–14 d precalving; TR TIME CAT_3: sample col-
lected 15–21 d precalving; TR TIME CAT_4: sample collected > 21 d precalving; TR TIME CAT_999: No transition period milk sample col-
lected.
period and once again highlighted the pivotal role IMI 
during the dry period has on the incidence and etiology 
of clinical mastitis in the subsequent lactation.
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